Immune checkpoint inhibitors in the treatment of HCC

C Donisi, M Puzzoni, P Ziranu, E Lai, S Mariani… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …

[HTML][HTML] Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art

A Facciorusso - World journal of gastroenterology, 2018 - ncbi.nlm.nih.gov
Transarterial chemoembolization (TACE) represents the current gold standard for
hepatocellular carcinoma (HCC) patients in intermediate stage. Conventional TACE …

Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma

R Golfieri, E Giampalma, M Renzulli, R Cioni… - British journal of …, 2014 - nature.com
Background: Transcatheter arterial chemoembolisation (TACE) is the treatment of choice for
intermediate stage hepatocellular carcinoma (HCC). Doxorubicin-loaded drug-eluting beads …

Self-fueling ferroptosis-inducing microreactors based on pH-responsive Lipiodol Pickering emulsions enable transarterial ferro-embolization therapy

C Wang, L Zhang, Z Yang, D Zhao… - National Science …, 2024 - academic.oup.com
Lipiodol chemotherapeutic emulsions remain one of the main choices for the treatment of
unresectable hepatocellular carcinoma (HCC) via transarterial chemoembolization (TACE) …

Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis

KI Bzeizi, M Arabi, N Jamshidi, A Albenmousa… - Cancers, 2021 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is the most common type of liver cancer
and accounts for approximately 6% of all human cancers. In this study, we performed a …

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

R Kloeckner, A Weinmann, F Prinz, D Pinto dos Santos… - BMC cancer, 2015 - Springer
Background To compare the overall survival of patients with hepatocellular carcinoma
(HCC) who were treated with lipiodol-based conventional transarterial chemoembolization …

Recent advances in medical management of hepatocellular carcinoma

K Ikeda - Hepatology Research, 2019 - Wiley Online Library
Transcatheter arterial therapies for hepatocellular carcinoma (HCC) have developed during
the last decade. A fine powder formulation of cisplatin and the new platinum agent miriplatin …

Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?

E Lai, G Astara, P Ziranu, A Pretta, M Migliari… - Critical Reviews in …, 2021 - Elsevier
Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy
has been explored in this disease in order to improve survival outcomes. Nowadays …

[HTML][HTML] Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a …

AM Romero, B van der Holt, FEJA Willemssen… - International Journal of …, 2023 - Elsevier
Purpose To compare transarterial chemoembolization delivered with drug eluting beads
(TACE-DEB) with stereotactioc body radiation therapy (SBRT) in patients with hepatocellular …

Drug-eluting beads versus conventional transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis

ZY Wang, CF **e, KL Feng, CM **ong, JH Huang… - Medicine, 2023 - journals.lww.com
Background: Transarterial chemoembolization (TACE) consists of conventional TACE
(cTACE) and drug-eluting beads TACE (DEB-TACE). The benefits of the 2 treatments remain …